AAAAAA

   
Results: 1-9 |
Results: 9
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection
Authors: Kim, D Wang, LP Caldwell, CG Chen, P Finke, PE Oates, B MacCoss, M Mills, SG Malkowitz, L Gould, SL DeMartino, JA Springer, MS Hazuda, D Miller, M Kessler, J Danzeisen, R Carver, G Carella, A Holmes, K Lineberger, J Schleif, WA Emini, EA
Citation: D. Kim et al., Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3099-3102
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection
Authors: Kim, D Wang, LP Caldwell, CG Chen, P Finke, PE Oates, B MacCoss, M Mills, SG Malkowitz, L Gould, SL DeMartino, JA Springer, MS Hazuda, D Miller, M Kessler, J Danzeisen, R Carver, G Carella, A Holmes, K Lineberger, J Schleif, WA Emini, EA
Citation: D. Kim et al., Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection, BIOORG MED, 11(24), 2001, pp. 3103-3106
1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity
Authors: Hale, JJ Budhu, RJ Holson, EB Finke, PE Oates, B Mills, SG MacCoss, M Gould, SL DeMartino, JA Springer, MS Siciliano, S Malkowitz, L Schleif, WA Hazuda, D Miller, M Kessler, J Danzeisen, R Holmes, K Lineberger, J Carella, A Carver, G Emini, E
Citation: Jj. Hale et al., 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity, BIOORG MED, 11(20), 2001, pp. 2741-2745
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
Authors: Dorn, CP Finke, PE Oates, B Budhu, RJ Mills, SG MacCoss, M Malkowitz, L Springer, MS Daugherty, BL Gould, SL DeMartino, JA Siciliano, SJ Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Cp. Dorn et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 259-264
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes
Authors: Finke, PE Meurer, LC Oates, B Mills, SG MacCoss, M Malkowitz, L Springer, MS Daugherty, BL Gould, SL DeMartino, JA Siciliano, SJ Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes, BIOORG MED, 11(2), 2001, pp. 265-270
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: A proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)4-[4-(substituted)piperidin-1yl]butanes
Authors: Finke, PE Meurer, LC Oates, B Shah, SK Loebach, JL Mills, SG MacCoss, M Castonguay, L Malkowitz, L Springer, MS Gould, SL DeMartino, JA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: A proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)4-[4-(substituted)piperidin-1yl]butanes, BIOORG MED, 11(18), 2001, pp. 2469-2473
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes
Authors: Finke, PE Oates, B Mills, SG MacCoss, M Malkowitz, L Springer, MS Gould, SL DeMartino, JA Carella, A Carver, G Holmes, K Danzeisen, R Hazuda, D Kessler, J Lineberger, J Miller, M Schleif, WA Emini, EA
Citation: Pe. Finke et al., Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes, BIOORG MED, 11(18), 2001, pp. 2475-2479
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L758,298, inhibit acute and delayed cisplatin-inducedemesis in ferrets
Authors: Tattersall, FD Rycroft, W Cumberbatch, M Mason, G Tye, S Williamson, DJ Hale, JJ Mills, SG Finke, PE MacCoss, M Sadowski, S Ber, E Cascieri, M Hill, RG MacIntyre, DE Hargreaves, RJ
Citation: Fd. Tattersall et al., The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L758,298, inhibit acute and delayed cisplatin-inducedemesis in ferrets, NEUROPHARM, 39(4), 2000, pp. 652-663
Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs
Authors: Hale, JJ Mills, SG MacCoss, M Dorn, CP Finke, PE Budhu, RJ Reamer, RA Huskey, SEW Luffer-Atlas, D Dean, BJ McGowan, EM Feeney, WP Chiu, SHL Cascieri, MA Chicchi, GG Kurtz, MM Sadowski, S Ber, E Tattersall, FD Rupniak, NMJ Williams, AR Rycroft, W Hargreaves, R Metzger, JM MacIntyre, DE
Citation: Jj. Hale et al., Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs, J MED CHEM, 43(6), 2000, pp. 1234-1241
Risultati: 1-9 |